cyrilzakka/clinical-trials huggingface dataset:
Rapid Sequence Intubation and Hemodynamic Disorders in the Operating Room: a Prospective Multicenter Observational Study

There is a great heterogeneity in the practice of rapid sequence induction in the operating room in the world. There are no recent data assessing the rate of implementation of the latest French formalized expert recommendations in clinical practice. In addition, the modalities for the management of haemodynamic disorders, particularly hypotensive disorders, during rapid sequence induction are not described in these recommendations, although these are frequent events with a non-zero morbidity mortality potential.

The goal of this prospective, observational, multicenter, anesthetic study is to describe the clinical practice of French anesthesiologists regarding the prevention of severe hemodynamic disorders during rapid sequence anesthetic induction in adult patients.

The primary outcome measure is the occurrence of a major haemodynamic disorder defined by a MBP ≤ 50 mmHg (or ≤ 40% of the reference value) and/or ≥ 110 mmHg and/or the occurrence of sustained arrhythmia not present at induction and/or cardiac arrest within the first 10 minutes after induction of anesthesia.

The clinical practices of pre-oxygenation, induction and intubation of French anesthesiologists and compliance with the formalized expert recommendations of 2017 and 2018 will also be studied secondarily. The elements for the prevention of gastric fluid inhalation, the organization and equipment used, the anesthetic and non-anesthetic drugs used, the clinical and paraclinical neurological and cardio-respiratory parameters and the nature of the complications following anaesthetic induction will be collected up to the 10th post-induction minute.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years' old
* Procedure requiring general anesthesia with oro or nasotracheal intubation
* Anesthetic management with indication of rapid sequence induction
* No objection after oral and written information to the patient

Exclusion Criteria:

* Age \< 18 years' old
* Impossible intubation planned
* Preoperative respiratory distress (SpO2 \< 90% in ambient air)
* Preoperative shock (MBP≤ 65 mmHg or vasopressive amines)
* Preoperative coma defined by a Glasgow score ≤ 12/15
* Patient in cardiopulmonary arrest
* Patients under guardianship or curatorship
A Novel Sperm Selection Method Provides Advantages Over Conventional Approaches

The goal of this clinical trial is to know if a novel sperm selection device (CA0) has a similar performance than the standard selection method in teratozoospermic and azoospermic men. The main questions it aims to answer are:

Does the CA0 sperm selection device increases the sperm concentration? Does the CA0 sperm selection device increases the sperm motility? What are the differences in sperm membrane potential when CA0 is used? Do intracellular Calcium levels change when CA0 is used? Does CA0 increase fertilization rates? Researchers will compare CA0 to the standard of care for sperm selection (density gradient centrifugation) to see if CA0 has similar performance

Participants will:

Provide a semen sample Have their semen sample analyzed, processed and used for assisted reproduction technologies


Eligibility Criteria:
Inclusion Criteria:

* Normozoospermic (18-35 years old) and teratozoospermic (18-60 years old) patients undergoing IVF/ICSI cyles with at least 2 days of sexual abstinence

Exclusion Criteria:

* Less than 4 oocytes collected during oocyte retrieval
* Total sperm count less than 30x10\^6
The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy

The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for six months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.

The DiaTRUST trial is an open-label randomized controlled trial with a six-month trial period. The trial will be conducted at Steno Diabetes Center North Jutland. Patients with T2D on insulin therapy will be randomized (3:1:1) to an intelligent telemonitoring group (intervention), telemonitoring alone (control), or a usual care group (control). Both telemonitoring groups will use an insulin pen, an activity tracker, a CGM, and a smartphone application throughout the trial period. Hospital staff (lab technicians and nurses) will monitor the telemonitoring groups' data and contact the subjects by telephone repeatedly throughout the trial period. For patients assigned to the intelligent telemonitoring group, decision support algorithms will provide hospital staff with insight and data overviews to support treatment evaluation and adjustment throughout the trial. Furthermore, patients in the intelligent telemonitoring group will have access to algorithms through a smartphone application that can provide a risk assessment before bed of nocturnal hypoglycemia. The usual care group will use a blinded CGM for the first 20 days after inclusion, 20 days before the second visit to the trial site, and 20 days before the end of trial and will use a blinded insulin pen for the entire period. The usual care groups' data will not be monitored during the trial.

Eligibility Criteria:
Inclusion Criteria:

* Adults ≥ 18 years.
* Diagnosis of T2D for at least 12 months prior to the day of screening.
* Patients who are being treated with insulin or about to start insulin treatment (insulin naïve) willing to travel to trial site in North Denmark to attend in-person visits.
* Have internet at home, have MitID, and willingness to use a smartphone and the other devices used in the trial
* Signed informed consent.
* Ability to understand and read Danish.

Exclusion Criteria:

* Pregnancy or breastfeeding.
* Major surgery is planned during the trial period.
* Cancer diagnosis within five years prior to inclusion.
* Participation in other interventional trials.
* Limited literacy affecting the use of trial devices.
* Patient who has worn a CGM monitor less than 6 months prior to the trial.
* Terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate.
* Patients treated with mixed insulin.
OCT-A and Amblyopia

Detect changes in retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia


Eligibility Criteria:
Inclusion Criteria:

1. Unilateral anisometropia.
2. Refractive error less than -6.00 D and +4.00 D.
3. Age less than 12 years.
4. No previous amblyopia treatments

Exclusion Criteria:

1. High refractive error. 2. Bilateral amblyopia. 3. Age more than 12 years.

-
Fracture Risk With Thiazolidinediones

Treatment with thiazolidinediones (TZD) has recently been reported to possibly increase the risk of fractures in a randomized trial exploring the efficacy of rosiglitazone (RSG), metformin, or glyburide encompassing 4360 patients with type 2 diabetes.

It is hypothesized that spironolactone, a diuretic that is broadly used for the treatment of fluid retention and edema associated with TZD, has a potential protective effect against bone fractures. However, to our knowledge, this has not been tested in diabetic patients treated with TZD. Amiloride is another diuretic that shares with spironolactone the anti mineralocorticoid ion gated channels activity and will be analysed in this study with regard to possible protective effect against bone fracture in combination with TZD.

This study is a nested case-control study conducted among type 2 diabetes subjects exposed to TZD. The study aims to explore if the risk of fracture is reduced among type 2 diabetic subjects exposed to spironolactone and TZD. The study will compare the odds of any low impact fracture, and hand, foot, upper arm, wrist, and hip fracture incidence in subjects treated with TZD+spironolactone and TZD+amiloride compared to subjects treated with TZD only.

The study population will consist of type 2 diabetes patients aged 18 -65 years old exposed to TZD. To be eligible for the study, a subject must have had at least one International Classification of Disease (ICD)-9 code for type 2 diabetes and have at least 6 months or at least 12 months of exposure to TZD (rosiglitazone \[RSG\], pioglitazone \[PIO\] or troglitazone) during their follow-up time available in the database.

Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.

Eligibility Criteria:
Inclusion Criteria:

* At least one ICD-9 code for type 2 diabetes
* At least 6 months or at least 12 months of exposure to TZD (RSG, PIO or troglitazone) during their follow-up time available in the database (The subject's study period begin date will be defined as the earliest date of their first TZD prescription. Subjects included in the study are required to have at least six months of follow-up time in the database prior to their first TZD prescription)

Exclusion Criteria:

* Subjects with a diagnosis of Paget's disease and osteomalacia
* A history of fracture, osteoporosis or cancer prior to the first prescription of TZD (study begin date)
Wii Fit Based Exercises and Proprioceptive Exercises in Diabetic Neuropathy Patients

This project is a Randomized clinical trial that will be conducted to check the effects of Wii Fit Based Exercises and Proprioceptive training on Balance and Fall Risk in patients with Diabetic Neuropathy, duration of study will be of 6months, convenient sampling will be used, subject following eligibility criteria from Riphah Rehabilitation Centre, Patients will be randomly allocated into two groups; Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking) \& Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before the session start and at the end of 6th Week.

Diabetes mellitus is a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high. Diabetic neuropathy is a serious diabetes complication that may affect as many as 50% of people with diabetes. The nerve damage associated with diabetic peripheral neuropathy (DPN) may reduce the proprioceptive inputs that contribute to decreased balance and an increased risk of falling. Wii Fit Balance Board improves balance in older adults through training. Wii Fit balance board showed significant improvement in balance and decrease the risk of fall. Proprioceptive training is an intervention that targets the improvement of proprioceptive function in patients. The aim of the current study is to determine the effects of Wii Fit Based exercises and proprioception training on balance and fall of risk in patients with Diabetic Neuropathy

Eligibility Criteria:
Inclusion Criteria:

* 40-80 years of age;
* Medical diagnoses of diabetes under regular medication control
* DN4 score ≥ 4
* Independent community ambulatory individuals;
* Intact cognition (Minimental State Examination score of \>24

Exclusion Criteria:

* Other neurological diseases such as dementia, Parkinson's disease, spinal cord injury, or stroke;
* Severe visual impairment, musculoskeletal disorders, unhealed plantar ulceration, lower limb amputation, poor cardiopulmonary function, or other diseases affecting walking ability or any other disease due to which individuals were unable to walk without assistance
* Any other condition associated with a high risk of falling
Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

The current study is being conducted in patients with major depression. The study aims to 1) investigate the combined effects of selective serotonin reuptake inhibitor (SSRI) and bupropion compared to SSRI alone on the improvements of depressive symptoms, fatigue, hypersomnia, and neurocognitive functions, 2) observe structural/functional/chemical changes using magnetic resonance imaging (MRI), 3) and examine a relationship between the improvements of depressive symptoms, fatigue, and hypersomnia and the neural changes.


Eligibility Criteria:
Inclusion Criteria:

* Men and women aged between 20 and 65
* Diagnosis of major depressive disorder (MDD) as assessed by the Structured Clinical Interview for DSM-IV (SCID-IV)
* Individuals who provided written consent for participation.

Exclusion Criteria:

* Presence of any major physical or neurological illness (e.g., head trauma, epilepsy, seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease, narrow-angle glaucoma, drug hypersensitivity, etc.)
* Diagnosis of any Axis I disorder other than MDD or presence of symptoms requiring hospitalization
* Intelligence quotient (IQ) below 80
* Contraindications to magnetic resonance imaging (e.g., pacemaker implantation, claustrophobia, etc.)
* Unstable medical illness or other abnormalities observed at the screening or laboratory tests
* Women who are pregnant, breastfeeding, or planning pregnancy
* Allergy or tolerance to the clinical trial medication
* Presence of any physical illness that contraindicates the clinical trial medication (e.g., epilepsy, history of uncontrollable narrow-angle glaucoma)
* Use of psychoactive medications that may affect brain imaging findings
Pattern Of Endoscopic Findings In Patients Underwent Upper Endoscopy In Sohag University Hospital

Diseases associated with upper gastrointestinal tract (UGIT) are common and associated with significant morbidity and mortality globally. Peptic ulcer disease, gastroesophageal reflux disease and cancers affect millions of people worldwide.

Upper endoscopy used for various diagnostic and therapeutic utic indications.

Upper GI symptoms are common complaints among the general population and the underlying diseases associated with them carrey significant morbidit.To the best of our knowledge , there is few data about the prevalence rate of various endoscopic findings among Egyptian ptients with UGI symptoms.

Upper gastrointestinal endoscopy (UGIE) is a valuable tool in the diagnosis and management of diseases affecting the esophagus, stomach and upper parts of the duodenum . In addition to direct inspection of the mucosa, endoscopies can be used for therapeutic interventions. Standard diagnostic indications for UGIE include upper gastrointestinal bleeding, evaluation of persistent epigastric pain despite an appropriate trial of therapy, persistent vomiting, dysphagia, anemia, symptoms or signs suggesting structural disease (e.g., anorexia, weight loss,),new onset dyspepsia in a patient older than 50 years of age, heartburn, oesophageal reflux symptoms that persist or recur despite appropriate therapy, surveillance of malignancy, and screening for oesophageal varices in cirrhotic patients. Therapeutic indications include Esophageal variceal ligation, upper GI bleeding control, foreign body removal, dilation or stenting of strictures, placement of feeding tubes, management of achalasia and endoscopic mucosal resection (EMR).

Eligibility Criteria:
Inclusion Criteria: all patients underwent upper endoscopy for various indication at endoscopy unit of Tropical Medicine and Gastroenterology Department, Sohag University Hospital during the specified period of the study

-

Exclusion Criteria:

* Absolute Contraindications

  * Perforated bowel.
  * Peritonitis.
  * Toxic megacolon in an unstable patient. Relative Contraindications
  * Severe neutropenia.
  * Coagulopathy.
  * Severe thrombocytopenia or impaired platelet function.• Increased risk of perforation including connective tissue disorders, recent bowel surgery or bowel obstruction.
  * Aneurysm of the abdominal and iliac aorta
Comparison of Longitudinal Blood Pressure and Arterial Stiffness in Preeclamptic Women After Delivery

The investigator measured the arterial stiffness using cardio-ankle vascular index (CAVI) test in patient with preeclampsia and normal pregnant women to evaluate the longitudinal change of CAVI and their predictors.

This study was a case control study and included 37 women with preeclampsia (PE group) and 36 normotensive women (control group) who gave birth to child at Seoul National University Bundang Hospital.

Cario-ankle vasuclar index (CAVI) was measured at one day, six months and one year after delivery in both group.

The investigator also checked the body weight, blood pressure, lipid profile, serum creatinine, aspartate transaminase (AST) and alanine transaminase (ALT) simultaneously with CAVI.

The relationship between the presence of preelampsia and longitudinal changes of CAVI, blood pressure and metabolic indices were evaluated using generalized estimating equation (GEE) method.

Eligibility Criteria:
Inclusion Criteria:

1. Case group : Women who were diagnosed preeclampsia based on the criteria of the International Society for the Study of Hypertension in Pregnancy
2. Control group : Normotensive women who gave birth to child at Seoul National University Bundang Hospital.

Exclusion Criteria:

* Women who were hemodynamically compromised or had bleeding complication after delivery were excluded.
Clinical Test of the MRgHIFU System on Uterine Fibroids

The objectives of this program are to verify the safety and effectiveness of the MRgHIFU system developed by the division of Medical Engineering of National Health Research Institutes (NHRI)

Between 25 % - 50 % of women of childbearing age have uterine fibroids. Also, 25% of women with fibroids suffer from the metrorrhagia, menorrhagia, dysmenorrheal or pelvic compression so that they don't have a good quality of life. The worse case is the fertility of patients with fibroids is hindered. The current clinical treatment is medication or surgery. Medication can only suppress the symptom temporarily when the hysterectomy method of removing part or all of uterus can cure the patient completely. However, the hysterectomy is an invasive operation and the women with fibroids who plan to have a baby don't accept this kind of treatment.

Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids has been developed and was approved by the US Food and Drug Administration (FDA) in 2004. The ultrasound waves emitted by the ultrasonic probe propagate through the skin, fat, muscle, soft tissues and converge on fibroids at focus. High energy/intensity at focus causes the thermal necrosis of the fibroid tissue in several seconds. The whole process of HIFU ablation of fibroids is monitored and guided by MR thermometery. The advantage of MR-HIFU modality includes no incision, outpatient treatment and few side effects.

The objectives of this program are to verify the safety and effectiveness of the MRgHIFU system developed by the division of Medical Engineering of National Health Research Institutes (NHRI), to achieve the clinical trial at the Chang-Gung Memorial Hospitals of Linkou and to commercialize the self-developed MRgHIFU system. The mission is to conduct the first-stage clinical test for 10 women with symptomatic uterine fibroids and to make two sets of HIFU system. Meanwhile, the impact of quality of life and satisfaction with treatment of the patients diagnosed with symptomatic uterine fibroids will be analyzed.

Eligibility Criteria:
Inclusion criteria:

1. Already sign in the Informed Consent Form。
2. The woman who want to operate the Hysteromyomectomy, and the volume of the fibromyoma is between 5-10 cm, will be included。
3. Woman age between 35\~45 years, and do not want to be pregnant
4. Abdominal circumference≦95 ㎝.
5. No pregnant.
6. MRI compatible.

Exclusion criteria:

1. Pregnant or Breast-feeding.
2. MRI uncompatible.
3. Woman who has scar in Abdomen.
4. Immunodeficiency or cancer.
5. Use the clinical medicine before 3 month age.
6. The woman who will not follow the project. -
Ankylosed Teeth Treatment by Bone Orthodontic Treatment

Codify the treatment of teeth by stiff Corticotomy technique. Evaluate the duration of treatment and tooth movement.

Codify the treatment of teeth by stiff Corticotomy technique. Evaluate the duration of treatment and tooth movement.

During treatment the teeth by stiff Corticotomy, millimeter measurements are performed on a cohort of patients with this pathology. These measures take place during normal clinical phases and on all media such as, plaster models, photographs and radiological examinations performed at the beginning, during and at the end of treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patient in need of orthodontic treatment and presenting one or more teeth stiff
* Can meet the requirement of orthodontic treatment (attendance, quality of brushing)
* Showing no indication against General Surgery

Exclusion Criteria:

* A patient against indication for orthodontic treatment : Root resorption of teeth adjacent to stiff teeth, Dental anchoring Deficiency by multiple agenesis or agenesis of the adjacent teeth to teeth stiff, Loss of periodontal support or active periodontal disease
* A patient against indication to treatment with Corticotomy : General Pathology against indicating surgery, Proximity root with no possibility of improvement orthodontic preparation
* Inability to maintain a good level of oral hygiene and good cooperation.